Rankings
▼
Calendar
TELO FY 2021 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$46M
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$138,131
Net Income
-$138,131
EPS (Diluted)
$-0.00
Cash Flow
Operating Cash Flow
-$119,396
Free Cash Flow
-$119,400
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$55,000
Total Liabilities
$138,131
Stockholders' Equity
-$83,131
Cash & Equivalents
$0
← Q1 2022
All Quarters